The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with rituximab for previously treated indolent non-Hodgkin lymphomas (iNHL).
John Leonard
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Pier Luigi Zinzani
Research Funding - Gilead Sciences
Wojciech Jurczak
Research Funding - Gilead Sciences
Mathias J. Rummel
Research Funding - Gilead Sciences
Gilles A. Salles
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences
Eva Kimby
Research Funding - Gilead Sciences
Hendrik-Tobias Arkenau
Research Funding - Gilead Sciences
Andrew John Davies
Research Funding - Gilead Sciences
David Michael Johnson
Employment or Leadership Position - Gilead Sciences
Shelley Evans
Employment or Leadership Position - Gilead Sciences
Roger D. Dansey
Employment or Leadership Position - Gilead Sciences
Wayne R. Godfrey
Employment or Leadership Position - Gilead Sciences
Brad S. Kahl
Consultant or Advisory Role - Gilead Sciences
Research Funding - Gilead Sciences